STOCK TITAN

Cingulate (CING) Financials

CING NASDAQ
FY2025 annual
Net Income -$22.4M n/m YoY
EPS (Diluted) -$4.44 YoY not available
Free Cash Flow -$17.4M n/m YoY
Operating Cash Flow -$17.2M n/m YoY
Market Cap $75.3M as of Oct 26, 2026
Price / Sales n/m no revenue reported
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 3.2x on $23.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CING SEC filings page.

This page shows Cingulate Inc. (CING) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CING FY2025

Cingulate has no reported revenue and relies on financing to fund development, while liabilities take a larger share of its balance sheet.

Operating cash flow was -$17.2M versus free cash flow of -$17.4M in FY2025, so reinvestment outside operations was small. That narrow gap, alongside a net loss of $22.4M and capex of $162K, indicates cash needs are primarily operating and development spending rather than asset expansion.

R&D spending was $9.8M while SG&A was $10.2M in FY2025, showing a cost structure split nearly evenly between development and overhead. Financing cash flow of $16.1M nearly matched operating cash outflow of $17.2M, making external funding central to the year's cash movement.

Liabilities rose 69.6% while equity fell 66.3% from FY2024 to FY2025, leaving less balance-sheet capacity to absorb losses. The current ratio moved from 2.5x to 1.2x, showing short-term coverage weakened even as total assets were nearly flat.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

Cingulate Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Cingulate Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Cingulate Inc. reported a net loss of $22.4M while operations used $17.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Cingulate Inc. reported an operating loss of $19.9M against $901K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$5.3M
YoYn/m
QoQn/m

Cingulate Inc.'s EBITDA was -$5.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$5.9M
YoYn/m
QoQn/m

Cingulate Inc. reported a net loss of $5.9M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.45
QoQn/m

Cingulate Inc. earned -$0.45 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow
-$6.0M
QoQn/m

Cingulate Inc. recorded an outflow of $6.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$28.4M
YoY+219.1%
QoQ+9.7%

Cingulate Inc. held $28.4M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding
15M
QoQ+9.5%

Cingulate Inc. had 15M shares outstanding in Q2 2026. Against the prior quarter it is up 9.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity
-25.0%
YoY+65.4pp
QoQ+24.3pp

Cingulate Inc.'s quarterly ROE was -25.0% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 65.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 24.3 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending
$1.5M
YoY-45.0%
QoQ-31.9%

Cingulate Inc. invested $1.5M in research and development in Q2 2026. This represents a decrease of 45.0% from the same quarter a year earlier. Against the prior quarter it is down 31.9%.

Capital Expenditures
$67K
QoQ+9.6%

Cingulate Inc. invested $67K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is up 9.6%.

Share Buybacks

Not reported for Q2 2026.

CING Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CING quarterly income statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
R&D Expenses$1.5M-45.0%$2.2M-1.7%N/A$2.8M+99.4%$2.7M+43.6%$2.2M+23.0%N/A$1.4M-63.6%
SG&A Expenses$3.9M+101.5%$5.7M+286.9%N/A$3.1M+69.8%$1.9M+47.1%$1.5M+30.0%N/A$1.9M+1.5%
Operating Income-$5.4Mn/m-$7.9Mn/mN/A-$6.0Mn/m-$4.6Mn/m-$3.7Mn/mN/A-$3.3Mn/m
EBITDA-$5.3Mn/m-$7.8Mn/mN/A-$5.9Mn/m-$4.5Mn/m-$3.5Mn/mN/A-$3.1Mn/m
Interest Expense$236K+10.6%$348K+66.1%N/AN/A$214K$210K+570.9%N/AN/A
Net Income-$5.9Mn/m-$9.3Mn/mN/A-$7.3Mn/m-$5.0Mn/m-$3.9Mn/mN/A-$4.1Mn/m
EPS (Basic)-$0.45-$0.95-$0.84-$1.35-$1.14-$1.06N/A-$2.34
EPS (Diluted)-$0.45-$0.95-$0.84-$1.35-$1.14-$1.06N/A-$2.34
Diluted Shares (Avg)13M10MN/A5M4M4MN/A2M

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

CING Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CING quarterly balance sheet
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Total Assets$33.1M+145.5%$30.9M+147.5%$15.1M+1.4%$10.5M-22.5%$13.5M+162.7%$12.5M+126.9%$14.9M+325.7%$13.6M+131.3%
Current Assets$30.2M+195.5%$27.9M+165.7%$12.0M-5.2%$7.4M-34.5%$10.2M+306.3%$10.5M+285.2%$12.7M+2088.2%$11.3M+290.8%
Cash & Equivalents$28.4M+219.1%$25.9M+172.0%$11.0M-10.3%$6.1M-39.1%$8.9M+2236.4%$9.5M+754.6%$12.2M+23196.9%$10.0M+405.5%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$9.6M+20.6%$12.0M+83.5%$12.6M+69.6%$7.0M+356.7%$8.0M+289.4%$6.5M+187.0%$7.4M-28.5%$1.5M-74.1%
Current Liabilities$8.6M+28.2%$11.0M+95.2%$10.3M+107.4%$5.9M+281.3%$6.7M+229.5%$5.6M+150.1%$5.0M-51.4%$1.5M-73.1%
Non-Current Liabilities$968K-20.9%$1.0M+12.1%$2.3M-7.6%$1.2Mn/m$1.2Mn/m$924K+2686.8%$2.4M+1703.8%$0-100.0%
Total Equity$23.5M+325.8%$18.9M+218.1%$2.5M-66.3%$3.5M-71.1%$5.5M+78.7%$5.9M+84.4%$7.5Mn/m$12.0Mn/m
Retained Earnings-$147.6Mn/m-$141.7Mn/m-$132.4Mn/m-$126.1Mn/m-$117.1Mn/m-$112.3Mn/m-$109.9Mn/m-$102.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CING Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CING quarterly cash flow statement
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Operating Cash Flow-$5.9Mn/m-$6.9Mn/m-$3.6Mn/m-$4.2Mn/m-$4.8Mn/m-$4.6Mn/m-$4.1Mn/m-$3.9Mn/m
Depreciation & Amortization$98K-33.2%$121K-26.7%$122K-24.0%$107K-35.4%$147K-10.3%$165K+1.0%$160K-7.0%$165K+6.9%
Stock-Based CompensationN/A$593K+65.8%N/AN/AN/A$358K+117.3%N/AN/A
Capital Expenditures$67K$61K$156K-21.3%$0-100.0%N/AN/A$198K+6.2%-$141Kn/m
Free Cash Flow-$6.0M-$7.0M-$3.8Mn/m-$4.2Mn/mN/AN/A-$4.3Mn/m-$4.0Mn/m
Investing Cash Flow-$67K-$61K-$156Kn/m$0-100.0%N/AN/A-$198Kn/m$141Kn/m
Financing Cash Flow$8.5M+102.7%$21.9M+1043.8%$8.6M+33.2%$1.5M-89.1%$4.2M+286.6%$1.9M-80.6%$6.4M+690.9%$13.4M+126.1%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CING Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CING quarterly financial ratios
MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Return on Equity-25.0%+65.4pp-49.4%+15.6ppN/A-211.3%-177.1pp-90.4%+14.3pp-65.0%+27.5ppN/A-34.3%
Return on Assets-17.8%+19.3pp-30.2%+0.7ppN/A-69.8%-39.4pp-37.0%+26.0pp-30.9%+23.2ppN/A-30.4%+71.5pp
Current Ratio3.50+2.0x2.55+0.7x1.16-1.4x1.26-6.1x1.52+0.3x1.87+0.7x2.55+2.5x7.35+6.8x
Liabilities-to-Equity0.41-1.0x0.64-0.5x5.01+4.0x2.03+1.9x1.44+0.8x1.10+0.4x0.990.13

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Cingulate Inc. CING FY2025 N/A -$22.4M N/A $75.3M —
Lexaria Bioscience Corp. LEXX FY2025 $706K -$11.9M N/A $6.2M —
Aspire-Lakewood Holdings, Inc. ASBP FY2025 $6K N/A N/A $11.4M —
Citius Pharmaceuticals Inc. CTXR FY2025 N/A -$37.4M N/A $12.3M —
CytoMed Therapeutics Limited GDTC FY2025 $252K -$3.1M N/A $11.1M —

Frequently Asked Questions

Is Cingulate Inc. profitable?

No, Cingulate Inc. (CING) reported a net loss of $22.4M in fiscal year 2025.

What is Cingulate Inc.'s earnings per share (EPS)?

Cingulate Inc. (CING) reported diluted earnings per share of -$4.44 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Cingulate Inc.'s EBITDA?

Cingulate Inc. (CING) had EBITDA of -$19.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Cingulate Inc. (CING) has a return on equity of -894.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Cingulate Inc. (CING) recorded an outflow of $17.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Cingulate Inc. (CING) recorded an outflow of $17.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Cingulate Inc. (CING) had $15.1M in total assets as of fiscal year 2025, including both current and long-term assets.

Cingulate Inc. (CING) invested $162K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Cingulate Inc. (CING) invested $9.8M in research and development during fiscal year 2025.

Cingulate Inc. (CING) had 12M shares outstanding as of fiscal year 2025.

Cingulate Inc. (CING) had a current ratio of 1.16 as of fiscal year 2025, which is considered adequate.

Cingulate Inc. (CING) had a liabilities-to-equity ratio of 5.01 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Cingulate Inc. (CING) had a return on assets of -148.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Cingulate Inc. (CING) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $75.3M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Cingulate Inc. (CING) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $75.3M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Cingulate Inc. (CING) held $11.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.2M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Cingulate Inc. (CING) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Cingulate Inc. (CING) reported a net loss of $22.4M while operations used $17.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Cingulate Inc. (CING) reported an operating loss of $19.9M against $901K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top